Literature DB >> 28533249

The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.

Eric Fleta-Soriano1, Katarína Smutná1, Javier P Martínez2, Cristina Lorca Oró3, S Kashif Sadiq1, Gilles Mirambeau3, Carmen Lopez-Iglesias4, Marta Bosch5, Albert Pol5,6, Mark Brönstrup7, Juana Diez8, Andreas Meyerhans2,6.   

Abstract

Soraphen A is a myxobacterial metabolite that blocks the acetyl-coenzyme A carboxylase of the host and was previously identified as a novel HIV inhibitor. Here, we report that soraphen A acts by reducing virus production and altering the gp120 virion content, impacting entry capacity and infectivity. These effects are partially reversed by addition of palmitic acid, suggesting that inhibition of HIV envelope palmitoylation is one of the mechanisms of antiviral action.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  HIV; broad-spectrum antiviral; fatty acid synthesis; host factor; human immunodeficiency virus; soraphen A

Mesh：

Substances：

Year:  2017        PMID： 28533249      PMCID： PMC5527598          DOI： 10.1128/AAC.00739-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity.

Authors:  I Rousso; M B Mixon; B K Chen; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Triton X-100 promotes a cholesterol-dependent condensation of the plasma membrane.

Authors:  Mercedes Ingelmo-Torres; Katharina Gaus; Albert Herms; Elena González-Moreno; Adam Kassan; Marta Bosch; Thomas Grewal; Francesc Tebar; Carlos Enrich; Albert Pol
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

3.  Optimized time-gated generalized polarization imaging of Laurdan and di-4-ANEPPDHQ for membrane order image contrast enhancement.

Authors:  Dylan M Owen; Katharina Gaus
Journal:  Microsc Res Tech       Date:  2010-06       Impact factor: 2.769

4.  Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles.

Authors:  Jayanta Bhattacharya; Paul J Peters; Paul R Clapham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes.

Authors:  R C Aloia; H Tian; F C Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

6.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

7.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

Review 8.  Multifaceted roles for lipids in viral infection.

Authors:  Nicholas S Heaton; Glenn Randall
Journal:  Trends Microbiol       Date:  2011-04-29       Impact factor: 17.079

9.  Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.

Authors:  G B Melikyan; R M Markosyan; H Hemmati; M K Delmedico; D M Lambert; F S Cohen
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

10.  Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay.

Authors:  Javier P Martinez; Bettina Hinkelmann; Eric Fleta-Soriano; Heinrich Steinmetz; Rolf Jansen; Juana Diez; Ronald Frank; Florenz Sasse; Andreas Meyerhans
Journal:  Microb Cell Fact       Date:  2013-09-24       Impact factor: 5.328
View more
  2 in total

1.  Physiologically Based Pharmacokinetic/Pharmacodynamic Model for the Treatment of Dengue Infections Applied to the Broad Spectrum Antiviral Soraphen A.

Authors:  Katharina Rox; Maxi Heyner; Jana Krull; Kirsten Harmrolfs; Valtteri Rinne; Juho Hokkanen; Gemma Perez Vilaro; Juana Díez; Rolf Müller; Andrea Kröger; Yuichi Sugiyama; Mark Brönstrup
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-30

Review 2.  Lipogenesis inhibitors: therapeutic opportunities and challenges.

Authors:  Battsetseg Batchuluun; Stephen L Pinkosky; Gregory R Steinberg
Journal:  Nat Rev Drug Discov       Date:  2022-01-14       Impact factor: 112.288
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.